|
2024 Conference Publication 3149 Real-world Australian experience with Ofatumumab in the MSBase registryMigocki, Margaret, Walt, Anneke Van der, Butzkueven, Helmut, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M, Lechner-Scott, Jeannette, John, Nevin, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Kalincik, Tomas, Macdonell, Richard, Slee, Mark and Schmitt, Birte (2024). 3149 Real-world Australian experience with Ofatumumab in the MSBase registry. BMJ Publishing Group Ltd. doi: 10.1136/bmjno-2024-anzan.127 |
|
2024 Conference Publication 2967 Utilisation of high efficacy therapy for managing multiple sclerosis in AustraliaMcCombe, Pamela, Butzkueven, Helmut, Samjoo, Imtiaz, Barnett, Michael, Broadley, Simon, Walt, Anneke Van der, Merschhemke, Martin, Adlard, Nicholas, Burke, Naomi, Riley, Nicholas and Walker, Rob (2024). 2967 Utilisation of high efficacy therapy for managing multiple sclerosis in Australia. BMJ Publishing Group Ltd. doi: 10.1136/bmjno-2024-anzan.23 |
|
2023 Conference Publication Novel real world evidence from MSGo, a digital support program for secondary progressive multiple sclerosis patients in Australia using SiponimodHardy, Todd, Aouad, Patrick, Barnett, Michael, Blum, Stefan, Broadley, Simon, Carroll, William, Crimmins, Denis, Griffiths, Dayna, Hodgkinson, Suzanne, Lechner-Scott, Jeannette, Lee, Andrew, Malhotra, Ram, McCombe, Pamela, Parratt, John, Plummer, Christopher, Van der Walt, Anneke, Martel, Kate and Walker, Rob (2023). Novel real world evidence from MSGo, a digital support program for secondary progressive multiple sclerosis patients in Australia using Siponimod. PACTRIMS 2022: 12th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, Singapore, Singapore, 24-26 November 2022. London, United Kingdom: Sage Publications. |
|
2022 Conference Publication Comparison of the effectiveness of ocrelizumab vs interferon β, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosisRoos, Izanne, Sharmin, Sifat, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, Walt, Anneke van der, Butzkueven, Helmut, Butler, Ernest, MacDonell, Richard, McCombe, Pamela, Slee, Mark, Malpas, Charles and Kalincik, Tomas (2022). Comparison of the effectiveness of ocrelizumab vs interferon β, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis. ANZAN Annual Scientific Meeting 2022, Melbourne, VIC Australia, 10-13 May 2022. London, United Kingdom: BMJ. doi: 10.1136/bmjno-2022-anzan.26 |
|
2022 Conference Publication Latitude, UVR and multiple sclerosis severityVitkova, Marianna, Diouf, Ibrahima, Malpas, Charles, Barnett, Michael, Hodgkinson, Suzanne, Butler, Ernest, Slee, Mark, Taylor, Bruce, Butzkueven, Helmut, Lechner-Scott, Jeanette, McCombe, Pamela, Vucic, Steve, Macdonell, Richard, Shaw, Cameron and Kalincik, Tomas (2022). Latitude, UVR and multiple sclerosis severity. ANZAN Annual Scientific Meeting 2022, Melbourne, VIC Australia, 10-13 May 2022. London, United Kingdom: BMJ. doi: 10.1136/bmjno-2022-anzan.29 |
|
2021 Conference Publication Real-world experience with cladribine tablets in the MSBase Registry (2942)Butzkueven, Helmut, Spelman, Timothy, Hodgkinson, Suzanne, Kalincik, Tomas, Buzzard, Katherine, Skabina, Olga, Madueño, Sara Eichau, Ayuso, Guillermo Izquierdo, Van der Walt, Anneke, Grand-Maison, Francois, Butler, Ernest, Prevost, Julie, McCombe, Pamela, Oh, Jiwon, Macdonell, Richard, Lechner-Scott, Jeannette, Van Pesch, Vincent, Duquette, Pierre, Prat, Alexandre, Girard, Marc, Kermode, Allan and Fabris, Jessica (2021). Real-world experience with cladribine tablets in the MSBase Registry (2942). 2021 AAN 73rd Annual Meeting, Virtual, 17-22 April 2021. Philadelphia, PA USA: Wolters Kluwer Health. doi: 10.1212/wnl.96.15_supplement.2942 |
|
2021 Conference Publication MRI patterns distinguish neuromyelitis optica spectrum disorder from multiple sclerosisClarke, Laura, Arnett, Simon, Bukhari, Wajih, Khalilidehkordi, Elham, Sanchez, Sofia Jimenez, O’Gorman, Cullen, Prain, Kerri, Woodhall, Mark, Silvestrini, Roger, Bundell, Christine, Abernethy, David, Bhuta, Sandeep, Blum, Stefan, Boggild, Mike, Boundy, Karyn, Brew, Bruce, Brownlee, Wallace, Butzkueven, Helmut, Carroll, William, Chen, Celia, Coulthard, Alan, Dale, Russell, Das, Chandi, Fabis-Pedrini, Marzena, Fulcher, David, Gillis, David, Hawke, Simon, Heard, Robert, Henderson, Andrew ... Broadley, Simon (2021). MRI patterns distinguish neuromyelitis optica spectrum disorder from multiple sclerosis. AAN 73rd Annual Meeting, Online, 17-22 April 2021. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.96.15_supplement.4128 |
|
2021 Conference Publication Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)Diouf, Ibrahima, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Patti, Francesco, Shaygannejad, Vahid, Ozakbas, Serkan, Ayuso, Guillermo Izquierdo, Madueño, Sara Eichau, Zakaria, Magd, Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand’Maison, Francois, Hamdy, Sherif, Sola, Patrizia, Ferraro, Diana, Grammond, Pierre, Turkoglu, Recai, Butzkueven, Helmut, Yamout, Bassem, Altintas, Ayse, Van Pesch, Vincent, Maimone, Davide ... Kalincik, Tomas (2021). Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107). AAN 73rd Annual Meeting, Online, 17-22 April 2021. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.96.15_supplement.4107 |
|
2020 Conference Publication Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort studyCorbett, Joel, Blum, Stefan, Boggild, Mike, Broadley, Simon and McCombe, Pamela (2020). Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort study. 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.1499 |
|
2020 Conference Publication Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple SclerosisKalincik, Tomas, Diouf, Ibrahima, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Ayuso, Guillermo Izquierdo, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, R. M. M., Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Cartechini, Elisabetta, Van Pesch, Vincent, Iuliano, Gerardo, Granella, Franco, Bergamaschi, Roberto, Fernandez Bolanos, Ricardo ... Butzkueven, Helmut (2020). Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
|
2020 Conference Publication Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 YearsCelius, Elisabeth G., Oh, Jiwon, Achiron, Anat, Compston, D Alastair S., Devonshire, Virginia, Hellwig, Kerstin, Hutton, George J., McCombe, Pamela, Moore, Marie, Simm, Renata Faria, Sousa, Livia, Vincent, Stephen G., Chung, Luke, Daizadeh, Nadia, Mitchell, Colin and Rog, David (2020). Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years. 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.169 |
|
2020 Conference Publication Predicting Long-Term Sustained Disability Progression in Multiple SclerosisSharmin, Sifat, Bovis, Francesca, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Ayuso, Guillermo Izquierdo, Eichau, Sara, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Hupperts, R. M. M., Alroughani, Raed, Boz, Cavit, Shaygannejad, Vijay, Van Pesch, Vincent, Kappos, Ludwig, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Turkoglu, Recai, Solaro, Claudio, Ramo-Tello, Cristina ... Kalincik, Tomas (2020). Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
|
2020 Conference Publication Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS)Maltby, Vicki, Lydon, Amanda, Monif, Mastura, Kilpatrick, Trevor, Butzkueven, Helmut, Taylor, Bruce, McCombe, Pamela, Hodgkinson, Suzanne, Fabis-Pedrini, Marzena, Kermode, Allan, Barnett, Michael, Kalincik, Tomas and Lechner-Scott, Jeannette (2020). Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS). 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.5285 |
|
2020 Conference Publication Determinants of Therapeutic Lag in Multiple SclerosisRoos, Izanne, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Ayuso, Guillermo Izquierdo, Madueno, Sara Eichau, Patti, Francesco, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ozakbas, Serkan, Sola, Patrizia, Ferraro, Diana, Bergamaschi, Roberto, Cartechini, Elisabetta, Sa, Maria Jose, Boz, Cavit, Grand-Maison, Francois, Lechner-Scott, Jeannette, Terzi, Murat, Granella, Franco, Alroughani, Raed, Iuliano, Gerardo ... Kalincik, Tomas (2020). Determinants of Therapeutic Lag in Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
|
2020 Conference Publication Determinants of Therapeutic Lag in Relapsing Multiple SclerosisRoos, I., Frascoli, F., Horakova, D., Havrdova, E. Kubala, Trojano, M., Izquierdo, G., Eichau, S., Patti, F., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grammond, P., Ozakbas, S., Sola, P., Ferraro, D., Bergamaschi, R., Cartechini, E., Sa, M. Jose, Boz, C., Grand'Maison, F., Lechner-Scott, J., Terzi, M., Granella, F., Alroughani, R., Iuliano, G., Hupperts, R., Spitaleri, D. ... Kalincik, T. (2020). Determinants of Therapeutic Lag in Relapsing Multiple Sclerosis. Conference of MS Research Australia, Melbourne, Australia, 31 October-1 November 2019. London, United Kingdom: Sage Publications. |
|
2020 Conference Publication Low dose Rituximab in the treatment of myasthenia gravisChan, Fiona, Swayne, Andrew, Gillis, David, Wong, Richard, Walsh, Michael, Henderson, Robert, McCombe, Pamela and Blum, Stefan (2020). Low dose Rituximab in the treatment of myasthenia gravis. 18th Biennial Clinical Neurophysiology Workshop of the Australian and New Zealand Association of Neurologists, Gold Coast, QLD, Australia, 29 September–2 October 2019. E Park, Shannon, Ireland: Elsevier . doi: 10.1016/j.clinph.2019.11.034 |
|
2020 Conference Publication Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)Hartung, H-P, Comi, G., Arnold, D. L., Boyko, A. N., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2020). Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study). In: Conference of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Singapore, Singapore, (NP60-NP61). 13-15 November 2019. |
|
2020 Conference Publication Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 YearsCelius, Elisabeth G., Oh, Jiwon, Achiron, Anat, Compston, D. Alastair S., Devonshire, Virginia, Hellwig, Kerstin, Hutton, George J., McCombe, Pamela, Moore, Marie, Simm, Renata Faria, Sousa, Livia, Vincent, Stephen G., Chung, Luke, Daizadeh, Nadia, Mitchell, Colin and Rog, David (2020). Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April - 1 May 2020. Philadelphia, PA United States: Lippincott Williams & Wilkins. |
|
2020 Conference Publication Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-upPelletier, D., Arnold, D. L., Bass, A. D., Boyko, A. N., Broadley, S., Comi, G., McCombe, P., Montalban, X., Pozzilli, C., Rovira, A., Selmaj, K. W., Singer, B. A., Vermersch, P., Chung, L., Poole, E. and Wray, S. (2020). Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, West Palm Beach, FL, United States, 27-29 February 2020. London, United Kingdom: Sage Publications. |
|
2020 Conference Publication Cladribine: a multicentre Long-term efficacy Biomarker Australian Study (CLOBAS)L-Scott, J., Maltby, V., Lydon, A., Monif, M., Kilpatrick, T., Butzkueven, H., Taylor, B., McCombe, P., Hodgkinson, S., Fabis-Pedrini, M., Kermode, A., Barnett, M. and Kalincik, Tomas (2020). Cladribine: a multicentre Long-term efficacy Biomarker Australian Study (CLOBAS). Conference of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Singapore, Singapore, 13-15 November 2019. London, United Kingdom: Sage. |
